Drug-induced thrombocytopenia and thrombosis: Evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial

[1]  M. J. Tafreshi,et al.  Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists. , 2006, The American journal of cardiology.

[2]  E. Topol,et al.  Thrombocytopenia Caused by Abciximab or Tirofiban and Its Association With Clinical Outcome in Patients Undergoing Coronary Stenting , 2004, Circulation.

[3]  R. Wynn,et al.  Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: implications for the etiology of thrombocytopenia. , 2003, Blood.

[4]  C. Cannon,et al.  Acute Thrombocytopenia in Patients Treated with the Oral Glycoprotein IIb/IIIa Inhibitors Xemilofiban and Orbofiban: Evidence for an Immune Etiology , 2002, Thrombosis and Haemostasis.

[5]  R. Aster,et al.  Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. , 2002, Blood.

[6]  R. Wynn,et al.  Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. , 2002, Blood.

[7]  C. Bode,et al.  Intrinsic activating properties of GP IIb/IIIa blockers. , 2001, Thrombosis research.

[8]  Second Symphony Investigators.  Randomized Trial of Aspirin, Sibrafiban, or Both for Secondary Prevention After Acute Coronary Syndromes , 2001, Circulation.

[9]  Deepak L. Bhatt,et al.  Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists: A Meta-Analysis of Phase III Multicenter Randomized Trials , 2001, Circulation.

[10]  P. Théroux,et al.  Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. , 2000, Journal of the American College of Cardiology.

[11]  A. Skene,et al.  Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. , 2000, Circulation.

[12]  R. Califf,et al.  Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. , 2000, American heart journal.

[13]  P Serruys,et al.  Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. , 2000, The New England journal of medicine.

[14]  C. Cannon,et al.  Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction. , 2000, The American journal of cardiology.

[15]  B. Sobel,et al.  Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa. , 2000, Cardiovascular research.

[16]  C. Bode,et al.  Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia. , 1999, The American journal of cardiology.

[17]  B E Sobel,et al.  Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects. , 1999, The American journal of cardiology.

[18]  R. Califf,et al.  Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. , 1999, Circulation.

[19]  V. Fuster,et al.  Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. , 1999, JAMA.

[20]  L. Horstman,et al.  Platelet microparticles: a wide-angle perspective. , 1999, Critical reviews in oncology/hematology.

[21]  P. Jumes,et al.  Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa. , 1999, Blood.

[22]  Y. Matsuzawa,et al.  Association Between Ligand-Induced Conformational Changes of Integrin IIbβ3 and IIbβ3-Mediated Intracellular Ca2+ Signaling , 1998 .

[23]  C. Bode,et al.  Induction of Fibrinogen Binding and Platelet Aggregation as a Potential Intrinsic Property of Various Glycoprotein IIb/IIIa (IIbβ3) Inhibitors , 1998 .

[24]  R. Califf,et al.  Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. , 1998, Journal of the American College of Cardiology.

[25]  R. Giugliano,et al.  Thrombocytopenia With GP IIb/IIIa Inhibitors: A Meta-Analysis , 1998 .

[26]  Y. Matsuzawa,et al.  Association between ligand-induced conformational changes of integrin IIbbeta3 and IIbbeta3-mediated intracellular Ca2+ signaling. , 1998, Blood.

[27]  C. Bode,et al.  Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. , 1998, Blood.

[28]  J. Kelton,et al.  Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. , 1994, Blood.

[29]  K. Lee,et al.  Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group. , 1994, Journal of the American College of Cardiology.

[30]  Xiaoping Du,et al.  Ligands “activate” integrin α IIb β 3 (platelet GPIIb-IIIa) , 1991, Cell.

[31]  Xiaoping Du,et al.  Ligands "activate" integrin alpha IIb beta 3 (platelet GPIIb-IIIa). , 1991, Cell.